- Spexis receives second extension for the publication of its 2023 annual report until July 31, 2024, releasing its unaudited financial statements and providing an update on its dispute with SPRIM.
- Spexis receives approval of an extension of the deadline for the publication of its 2023 annual report and audited financials until latest May 31, 2024.
- Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Key statistics
On Friday, Spexis AG (SPEX:SWX) closed at 0.0618, 406.56% above the 52 week low of 0.0122 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0688 |
---|---|
High | 0.0688 |
Low | 0.056 |
Bid | 0.057 |
Offer | 0.062 |
Previous close | 0.0644 |
Average volume | 173.30k |
---|---|
Shares outstanding | 67.66m |
Free float | 33.99m |
P/E (TTM) | -- |
Market cap | 4.18m CHF |
EPS (TTM) | -0.2547 CHF |
Data delayed at least 15 minutes, as of May 31 2024 16:30 BST.
More ▼